News

The FDA has granted AbbVie’s potential first-in-class therapy C2N-8E12 orphan drug designation for the treatment of a rare neurodegenerative disorder.

Amgen’s leukaemia immunotherapy Blincyto has demonstrated complete remission in a phase II trial testing the drug in a new indication.

Baxter spin out Baxalta has unveiled data showing that its long-acting haemophilia drug Adynovate is better than predecessor Advate at clotting blood and preventing serious bleeds.

Novartis’ high-dose malaria medicine Coartem has received WHO prequalification, potentially paving the way for as many as 25 million patients in Africa to access to the drug.

The British Medical Association and the Health Secretary seem at loggerheads over the logistics of a seven-day National Health Service, with Jeremy Hunt telling the doctor’s union he will impose a new contract if negotiations to support the plans are unsuccessful.

Organiser PharmaTimes Media invites healthcare communications agencies to seize the opportunity to develop their skills and abilities.

European regulators have approved Bristol-Myers Squibb’s Evotaz pills in combination with other antiretroviral agents for the treatment of adult patients infected with HIV-1.

UK biotech Immuncore will be celebrating the success of a private financing round that has added some $320 million (£205 million) to its books, breaking the European record.

Adam Chapman, Senior Brand Manager at Lundbeck winner of Brand Manager of the Year 2014 at the PharmaTimes Marketer of the Year awards, explains the value of entering the PharmaTimes Marketer of the Year competition:

Sanofi has unveiled plans to carve up its operations into five global business units in the hope of maximising growth opportunities and optimising innovation and new drug development.

Almirall took centre stage at the PharmaTimes Sales & MSL Awards 2015 on July 9, taking home the prize for Sales Company of the Year, along with Key Account Manager of the Year, which was won by Faruk Dasu.

AstraZeneca has hooked up with Vida Health to launch a new smartphone app designed to speed up the recovery of patients who have suffered a heart attack. 

Another day, another pharma-academia hook-up, and this time its Bristol-Myers Squibb and the Medical University of South Carolina combining forces to study fibrotic diseases.

Celgene is laying more than $7 billion on the table to buy San Diego-based biotech Receptos, in a move that will significantly boost its inflammation and immunology portfolio.

GlaxoSmithKline, the Medical Research Council and UK academia are working together on a unique open innovation research initiative which strives to improve understanding of inflammatory diseases in the hope of paving the way for new treatments.